Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO)

Q: What does CUSIP 98422T100 represent in this 13F holders report?

CUSIP 98422T100 is the security identifier for XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

Q: How many institutions held XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share in Q1 2022?

41 institutional investors reported XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share for Q1 2022. Use the holders table for investor-level position and value details.

CUSIP: 98422T100

Q1 2022 13F Holders as of 31 Mar 2022

Type / Class: Equity / Common Stock, par value $0.0001 per share
Shares outstanding: 6,426,426
Total 13F shares: 18,775,939
Share change: -217,467
Total reported value: $132,746,000
Price per share: $7.07
Number of holders: 41
Value change: -$2,569,332
Number of buys: 10
Number of sells: 17

Security key

98422T100

Report period

Q1 2022

Institutions

Top holders

XLO full security history Newer quarter: Q2 2022 Previous quarter: Q4 2021 Xilio Therapeutics, Inc. SEC filings Xilio Therapeutics, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Reporting periods

Holder history for CUSIP 98422T100

Newer quarter: Q2 2022 Previous quarter: Q4 2021

Recent filing periods:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Bain Capital Life Sciences Investors, LLC	13F 3/4/5	Company · 10%+ Owner	44%	2,805,413	$44,887,000	—	31 Dec 2021	13F 3/4/5
Atlas Venture Life Science Advisors, LLC	13F	Company	43%	2,759,344	$44,150,000	—	31 Dec 2021	13F
FMR LLC	13F 3/4/5	Company · Other*	40%	2,570,270	$41,125,000	—	31 Dec 2021	13F 3/4/5
DEERFIELD MANAGEMENT COMPANY, L.P.	13F	Company	34%	2,154,061	$33,739,000	—	31 Dec 2021	13F
RA CAPITAL MANAGEMENT, L.P.	13F	Company	31%	2,002,217	$32,035,000	—	31 Dec 2021	13F
RiverVest Venture Management LLC	13F	Company	22%	1,441,444	$23,063	—	31 Dec 2021	13F
Rock Springs Capital Management LP	13F 3/4/5	Company · 10%+ Owner	19%	1,191,094	$19,058,000	—	31 Dec 2021	13F 3/4/5
AJU IB Investment Co., Ltd.	13F	Company	10%	667,742	$10,684	—	31 Dec 2021	13F
Soleus Capital Management, L.P.	13F	Company	7.4%	477,495	$7,640,000	—	31 Dec 2021	13F
Artal Group S.A.	13F	Company	7%	450,000	$7,200,000	—	31 Dec 2021	13F
VANGUARD GROUP INC	13F	Company	6.6%	424,224	$6,788,000	—	31 Dec 2021	13F
HARVARD MANAGEMENT CO INC	13F	Company	6.5%	416,059	$6,657,000	—	31 Dec 2021	13F
NORGES BANK	13F	Company	6.2%	400,000	$6,400,000	—	31 Dec 2021	13F
BlackRock Finance, Inc.	13F	Company	5%	324,094	$5,184,000	—	31 Dec 2021	13F
FIL Ltd	13F 3/4/5	Company · Other*	3.4%	218,705	$3,499,000	—	31 Dec 2021	13F 3/4/5
Monashee Investment Management LLC	13F	Company	3.3%	214,253	$3,428,000	—	31 Dec 2021	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	2.1%	134,185	$2,146,000	—	31 Dec 2021	13F
NORTHERN TRUST CORP	13F	Company	0.98%	63,034	$1,009,000	—	31 Dec 2021	13F
STATE STREET CORP	13F	Company	0.92%	59,210	$947,000	—	31 Dec 2021	13F
CAAS CAPITAL MANAGEMENT LP	13F	Company	0.58%	37,019	$592,000	—	31 Dec 2021	13F
Ghisallo Capital Management LLC	13F	Company	0.47%	30,000	$480,000	—	31 Dec 2021	13F
DAVIDSON KEMPNER CAPITAL MANAGEMENT LP	13F	Company	0.45%	29,000	$458,000	—	31 Dec 2021	13F
MARSHALL WACE, LLP	13F	Company	0.31%	20,189	$324,000	—	31 Dec 2021	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.25%	16,100	$258,000	—	31 Dec 2021	13F
Bank of New York Mellon Corp	13F	Company	0.22%	14,238	$228,000	—	31 Dec 2021	13F
JPMORGAN CHASE & CO	13F	Company	0.18%	11,686	$187,000	—	31 Dec 2021	13F
Nuveen Asset Management, LLC	13F	Company	0.18%	11,284	$181,000	—	31 Dec 2021	13F
Granite Point Capital Management, L.P.	13F	Company	0.16%	10,000	$160,000	—	31 Dec 2021	13F
NEW YORK STATE COMMON RETIREMENT FUND	13F	Company	0.09%	5,568	$89,000	—	31 Dec 2021	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.07%	4,774	$76,000	—	31 Dec 2021	13F
DEUTSCHE BANK AG\	13F	Company	0.07%	4,508	$72,000	—	31 Dec 2021	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.07%	4,462	$71,000	—	31 Dec 2021	13F
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	13F	Company	0.06%	4,078	$65,000	—	31 Dec 2021	13F
UBS Group AG	13F	Company	0.06%	3,977	$64,000	—	31 Dec 2021	13F
AMERICAN INTERNATIONAL GROUP, INC.	13F	Company	0.06%	3,944	$63,000	—	31 Dec 2021	13F
CITIGROUP INC	13F	Company	0.03%	2,194	$35,000	—	31 Dec 2021	13F
STRS OHIO	13F	Company	0.03%	1,700	$27,000	—	31 Dec 2021	13F
ROYAL BANK OF CANADA	13F	Company	0.02%	1,585	$25,000	—	31 Dec 2021	13F
MORGAN STANLEY	13F	Company	0.02%	1,038	$17,000	—	31 Dec 2021	13F
Tower Research Capital LLC (TRC)	13F	Company	0.01%	961	$15,000	—	31 Dec 2021	13F
Legal & General Group Plc	13F	Company	0.01%	698	$11,000	—	31 Dec 2021	13F
Ameritas Investment Partners, Inc.	13F	Company	0.01%	573	$9,000	—	31 Dec 2021	13F
SV7 Impact Medicine Fund LP	3/4/5	10%+ Owner	— class O/S missing	3,227,264	$2,678,630	—	26 Oct 2021	3/4/5
James E. Flynn	3/4/5	Possible Member of 10% Group, 10%+ Owner	— class O/S missing	2,287,944	$1,898,994	—	26 Oct 2021	3/4/5
TAKEDA PHARMACEUTICAL CO LTD	3/4/5	10%+ Owner	— class O/S missing	1,475,121	$1,224,350	—	26 Oct 2021	3/4/5
RiverVest Venture Fund IV, L.P.	3/4/5	10%+ Owner	— class O/S missing	1,441,444	$1,196,399	—	26 Oct 2021	3/4/5
BAY CITY CAPITAL LLC	3/4/5	10%+ Owner	— class O/S missing	1,129,490	$937,477	—	26 Oct 2021	3/4/5
Merck KGaA	3/4/5	10%+ Owner	— class O/S missing	680,825	$565,085	—	26 Oct 2021	3/4/5
Alexandria Venture Investments, LLC	3/4/5	10%+ Owner	— class O/S missing	166,423	$138,131	—	26 Oct 2021	3/4/5
Simon M. Tomlinson	3/4/5	10%+ Owner	— class O/S missing	131,117	$108,827	—	21 Oct 2021	3/4/5

Institutional Holders of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) as of Q1 2022

As of 31 Mar 2022, Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) was held by 41 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 18,775,939 shares. The largest 10 holders included Bain Capital Life Sciences Investors, LLC, Atlas Venture Life Science Advisors, LLC, FMR LLC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), RA CAPITAL MANAGEMENT, L.P., RiverVest Venture Management LLC, Rock Springs Capital Management LP, AJU IB Investment Co., Ltd., Soleus Capital Management, L.P., and Artal Group S.A.. This page lists 41 institutional shareholders reporting positions in this security for the Q1 2022 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2022 vs Q4 2021 Across Filers

Q4 2021 holders

Q1 2022 holders

Holder diff

Investor	Q4 2021 Shares	Q1 2022 Shares	Share Diff	Share Chg %	Q4 2021 Value $	Q1 2022 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.